Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Equity Average (2022 - 2025)

Historic Equity Average for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $360.1 million.

  • Entrada Therapeutics' Equity Average fell 1550.39% to $360.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.1 million, marking a year-over-year decrease of 1550.39%. This contributed to the annual value of $335.5 million for FY2024, which is 4750.88% up from last year.
  • Per Entrada Therapeutics' latest filing, its Equity Average stood at $360.1 million for Q3 2025, which was down 1550.39% from $398.4 million recorded in Q2 2025.
  • Entrada Therapeutics' Equity Average's 5-year high stood at $426.2 million during Q3 2024, with a 5-year trough of $218.3 million in Q2 2023.
  • Moreover, its 4-year median value for Equity Average was $261.3 million (2022), whereas its average is $306.0 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Equity Average tumbled by 1816.73% in 2023, and later surged by 8792.47% in 2024.
  • Over the past 4 years, Entrada Therapeutics' Equity Average (Quarter) stood at $222.9 million in 2022, then rose by 9.7% to $244.5 million in 2023, then soared by 74.05% to $425.6 million in 2024, then dropped by 15.38% to $360.1 million in 2025.
  • Its Equity Average stands at $360.1 million for Q3 2025, versus $398.4 million for Q2 2025 and $423.0 million for Q1 2025.